TFDA-2024-0031-V331

Type II variation for application TFDA-2024-0031. Type II variation: New Dosage Strength for Kcluximab — critical change

Variation Number
TFDA-2024-0031-V331
Type
Type II
Application
TFDA-2024-0031
Change
CHG-2022-0031
Status
Draft
Fee
€53,805
Submitted
2023-12-03
Approved
—
Description

Type II variation: New Dosage Strength for Kcluximab — critical change